Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14914789 | 0.87 | KCNJ1 (0.39) | ALDH1A1POLBLMNAKCNJ1CYP1A2 | |
| SCHEMBL14914293 | 0.80 | ALDH1A1 (0.36) | ALDH1A1POLBF2RL3LMNAKMT2A | |
| SCHEMBL14913483 | 0.78 | ALDH1A1 (0.34) | ALDH1A1POLBHTTKMT2A | |
| SCHEMBL12179475 | 0.75 | CYP1A2 (0.43) | ALDH1A1F2RL3LMNACYP1A2KMT2A | |
| SCHEMBL2475555 | 0.74 | F2 (0.44) | ALDH1A1POLBF2RL3LMNACYP1A2 | |
| SCHEMBL3750648 | 0.73 | F2RL3 (0.40) | ALDH1A1F2RL3LMNACYP1A2HTT | |
| SCHEMBL3644933 | 0.72 | MAPT (0.44) | ALDH1A1F2RL3LMNACYP1A2HTT | |
| SCHEMBL2471752 | 0.72 | MEN1 (0.41) | ALDH1A1POLBF2RL3LMNACYP1A2 | |
| SCHEMBL12179656 | 0.71 | ALDH1A1 (0.37) | ALDH1A1POLBLMNACYP1A2KMT2A | |
| SCHEMBL9054298 | 0.70 | ALDH1A1 (0.48) | ALDH1A1POLBCYP1A2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563762-B1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER IP GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8802860-B2 | Method for producing substituted pyridin-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | PNPO, CYP4B1, DPYD | ALDH1A1 488/4885POLB 1848/4885F2RL3 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.